Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a new drug match the standard for liver cancer treatment?

NCT ID NCT06114082

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial is testing whether a chemotherapy drug called idarubicin works as well as the standard drug doxorubicin when used in a procedure called transarterial chemoembolization (TACE) for liver cancer. TACE delivers chemotherapy directly to the tumor and blocks its blood supply. The study will include adults with hepatocellular carcinoma who have not had prior treatment. The goal is to see if idarubicin is not inferior to doxorubicin in shrinking or controlling tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
idarubicin
What this could lead to
If idarubicin proves as effective as doxorubicin, it could offer an alternative chemoembolization option for liver cancer patients, potentially with different side effects or benefits.
What could go wrong
This is a phase 2 trial, so results are preliminary. The study may not show a significant difference, or idarubicin could have unforeseen side effects. Non-inferiority trials also have specific statistical limitations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

128 people

The number who actually took part.

Started

Jul 2023

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 19 or above. 2. Patients diagnosed with HCC either histologically and/or radiologically (LI-RADS 4 or 5). 3. Patients with five or fewer tumors. 4. Patients in which the largest tumor is 5 cm or less in diameter. 5. Patients with no prior treatment experience for HCC. 6. Patients categorized as Child-Pugh class A or B. 7. Patients with an Eastern Cooperative Oncology Group performance status of 2 or below. 8. Patients without severe functional abnormalities of major organs: the following results from a blood test conducted within a month prior to the procedure must be satisfied: * WBC count ≤ 12,000 / mm3 * Absolute neutrophil count ≥ 1,500 /mm3 * Hemoglobin ≥ 8.0 g/dL * Total bilirubin ≤ 3.0 mg/dL * eGFR ≥ 30 mL/min/1.73 m2 * Patients deemed clinically most suitable to receive TACE through hepatologist, hepatic surgeon, or multidisciplinary consultation: patients for whom other treatments such as liver transplantation/surgery/ablation are realistically impossible or, even if technically possible, do not have significant clinical benefits compared to TACE. * Patients who have understood sufficiently about this clinical trial and have given written consent to participate. * Fertile women capable of effective contraception for at least 6.5 months after TACE, and men with fertile female partners capable of effective contraception for at least 3.5 months after TACE. Exclusion Criteria: 1. Patients with HCC involving the portal vein or hepatic vein. 2. Patients with extrahepatic spread of HCC 3. Patients diagnosed with a cancer other than HCC within 2 years of enrollment. 4. Patients who have undergone a biliary-intestinal anastomosis. 5. Patients for whom the use of idarubicin or doxorubicin is contraindicated (including severe heart failure, arrhythmia, hypersensitivity to anthracycline chemotherapy, pregnant or nursing women, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul National University Hospital

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.